Predicted protein targets (top 7)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | NTSR1 | P30989 | 3/20 | 0.59 |
| ▸ | CALCR | P30988 | 4/20 | 0.59 |
| ▸ | NPY2R | P49146 | 7/20 | 0.58 |
| ▸ | NPY4R | P50391 | 7/20 | 0.58 |
| ▸ | NPY5R | Q15761 | 7/20 | 0.58 |
| ▸ | NPY1R | P25929 | 5/20 | 0.58 |
| ▸ | OPRD1 | P41143 | 1/20 | 0.57 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL29811064 | 0.92 | CALCR (0.66) | CALCRNPY2RNPY4RNPY5RNPY1R | |
| SCHEMBL30277958 | 0.91 | NPY2R (0.62) | NTSR1CALCRNPY2RNPY4RNPY5R | |
| SCHEMBL31182911 | 0.90 | CALCR (0.65) | CALCRNPY2RNPY4RNPY5RNPY1R | |
| SCHEMBL29679500 | 0.90 | CALCR (0.64) | NTSR1CALCRNPY2RNPY4RNPY5R | |
| SCHEMBL30432228 | 0.89 | NPY2R (0.62) | NTSR1CALCRNPY2RNPY4RNPY5R | |
| SCHEMBL30567778 | 0.89 | CALCR (0.66) | CALCRNPY2RNPY4RNPY5RNPY1R | |
| SCHEMBL30906377 | 0.89 | NPY2R (0.71) | CALCRNPY2RNPY4RNPY5RNPY1R | |
| SCHEMBL29479848 | 0.89 | F2 (0.63) | NTSR1CALCRNPY2RNPY4RNPY5R | |
| SCHEMBL30906483 | 0.88 | NPY2R (0.63) | NTSR1CALCRNPY2RNPY4RNPY5R | |
| SCHEMBL31182783 | 0.88 | CALCR (0.63) | CALCRNPY2RNPY4RNPY5RNPY1R |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 9 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-12629409-B2 | Vaccine | GLAXOSMITHKLINE BIOLOGICALS SA (BE) | 2026-05-19 | — | — | US | disclosed |
| US-20240226261-A9 | VACCINE | GLAXOSMITHKLINE BIOLOGICALS SA (BE) | 2024-07-11 | — | — | US | disclosed |
| US-20240131136-A1 | VACCINE | GLAXOSMITHKLINE BIOLOGICALS SA (BE) | 2024-04-25 | — | — | US | disclosed |
| US-11844828-B2 | Vaccine | GLAXOSMITHKLINE BIOLOGICALS SA (BE) | 2023-12-19 | — | — | US | disclosed |
| US-20230248816-A9 | PROCESS FOR PREPARING A COMPOSITION COMPRISING A PROTEIN D POLYPEPTIDE | GLAXOSMITHKLINE BIOLOGICALS SA (BE) | 2023-08-10 | — | — | US | disclosed |
| US-20230066762-A1 | IMMUNOGENIC COMPOSITION | GLAXOSMITHKLINE BIOLOGICALS SA (BE) | 2023-03-02 | — | — | US | disclosed |
| US-20220288190-A1 | PROCESS FOR PREPARING A COMPOSITION COMPRISING A PROTEIN D POLYPEPTIDE | GLAXOSMITHKLINE BIOLOGICALS SA (BE) | 2022-09-15 | — | — | US | disclosed |
| US-20220152182-A1 | VACCINE | GLAXOSMITHKLINE BIOLOGICALS SA (BE) | 2022-05-19 | — | — | US | disclosed |
| US-11266731-B2 | Vaccine | GLAXOSMITHKLINE BIOLOGICALS SA (BE) | 2022-03-08 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (4 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20220288190-A1 | PROCESS FOR PREPARING A COMPOSITION COMPRISING A PROTEIN D POLYPEPTIDE | CFD, PEPD, SERPINA6 | NTSR1 2610/4885CALCR 415/4885NPY2R 2991/4885 |
| US-20230248816-A9 | PROCESS FOR PREPARING A COMPOSITION COMPRISING A PROTEIN D POLYPEPTIDE | CFD, PEPD, SERPINA6 | NTSR1 2610/4885CALCR 415/4885NPY2R 2991/4885 |
| US-12629409-B2 | Vaccine | MRPL21, STT3B, CD47 | NTSR1 2817/4885CALCR 1824/4885NPY2R 658/4885 |
| US-20230066762-A1 | IMMUNOGENIC COMPOSITION | CXCL10, CCL2, CCL11 | NTSR1 1645/4885CALCR 1308/4885NPY2R 3202/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.